Global Duchenne Muscular Dystrophy Drugs Market Research Report 2023

Report ID: 1974208 | Published Date: Jan 2025 | No. of Page: 93 | Base Year: 2024 | Rating: 3.8 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
        1.2.2 Molecular-based Therapies
        1.2.3 Steroid Therapy
        1.2.4 Other
    1.3 Market by Application
        1.3.1 Global Duchenne Muscular Dystrophy Drugs Market Share by Application: 2017 VS 2021 VS 2028
        1.3.2 Hospitals
        1.3.3 Clinics
        1.3.4 Others
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Duchenne Muscular Dystrophy Drugs Market Perspective (2017-2028)
    2.2 Duchenne Muscular Dystrophy Drugs Growth Trends by Region
        2.2.1 Duchenne Muscular Dystrophy Drugs Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Duchenne Muscular Dystrophy Drugs Historic Market Size by Region (2017-2022)
        2.2.3 Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Region (2023-2028)
    2.3 Duchenne Muscular Dystrophy Drugs Market Dynamics
        2.3.1 Duchenne Muscular Dystrophy Drugs Industry Trends
        2.3.2 Duchenne Muscular Dystrophy Drugs Market Drivers
        2.3.3 Duchenne Muscular Dystrophy Drugs Market Challenges
        2.3.4 Duchenne Muscular Dystrophy Drugs Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Duchenne Muscular Dystrophy Drugs Players by Revenue
        3.1.1 Global Top Duchenne Muscular Dystrophy Drugs Players by Revenue (2017-2022)
        3.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Players (2017-2022)
    3.2 Global Duchenne Muscular Dystrophy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Duchenne Muscular Dystrophy Drugs Revenue
    3.4 Global Duchenne Muscular Dystrophy Drugs Market Concentration Ratio
        3.4.1 Global Duchenne Muscular Dystrophy Drugs Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Duchenne Muscular Dystrophy Drugs Revenue in 2021
    3.5 Duchenne Muscular Dystrophy Drugs Key Players Head office and Area Served
    3.6 Key Players Duchenne Muscular Dystrophy Drugs Product Solution and Service
    3.7 Date of Enter into Duchenne Muscular Dystrophy Drugs Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Duchenne Muscular Dystrophy Drugs Breakdown Data by Type
    4.1 Global Duchenne Muscular Dystrophy Drugs Historic Market Size by Type (2017-2022)
    4.2 Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Type (2023-2028)
5 Duchenne Muscular Dystrophy Drugs Breakdown Data by Application
    5.1 Global Duchenne Muscular Dystrophy Drugs Historic Market Size by Application (2017-2022)
    5.2 Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Duchenne Muscular Dystrophy Drugs Market Size (2017-2028)
    6.2 North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2017-2022)
    6.3 North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2028)
    6.4 United States
    6.5 Canada
7 Europe
    7.1 Europe Duchenne Muscular Dystrophy Drugs Market Size (2017-2028)
    7.2 Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2017-2022)
    7.3 Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2028)
    7.4 Germany
    7.5 France
    7.6 U.K.
    7.7 Italy
    7.8 Russia
    7.9 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size (2017-2028)
    8.2 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Country (2017-2022)
    8.3 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2028)
    8.4 China
    8.5 Japan
    8.6 South Korea
    8.7 Southeast Asia
    8.8 India
    8.9 Australia
9 Latin America
    9.1 Latin America Duchenne Muscular Dystrophy Drugs Market Size (2017-2028)
    9.2 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2017-2022)
    9.3 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2028)
    9.4 Mexico
    9.5 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size (2017-2028)
    10.2 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country (2017-2022)
    10.3 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2028)
    10.4 Turkey
    10.5 Saudi Arabia
    10.6 UAE
11 Key Players Profiles
    11.1 Biogen
        11.1.1 Biogen Company Detail
        11.1.2 Biogen Business Overview
        11.1.3 Biogen Duchenne Muscular Dystrophy Drugs Introduction
        11.1.4 Biogen Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
        11.1.5 Biogen Recent Development
    11.2 Roche
        11.2.1 Roche Company Detail
        11.2.2 Roche Business Overview
        11.2.3 Roche Duchenne Muscular Dystrophy Drugs Introduction
        11.2.4 Roche Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
        11.2.5 Roche Recent Development
    11.3 Daiichi Sankyo
        11.3.1 Daiichi Sankyo Company Detail
        11.3.2 Daiichi Sankyo Business Overview
        11.3.3 Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Introduction
        11.3.4 Daiichi Sankyo Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
        11.3.5 Daiichi Sankyo Recent Development
    11.4 Pfizer
        11.4.1 Pfizer Company Detail
        11.4.2 Pfizer Business Overview
        11.4.3 Pfizer Duchenne Muscular Dystrophy Drugs Introduction
        11.4.4 Pfizer Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
        11.4.5 Pfizer Recent Development
    11.5 Cumberland Pharmaceuticals
        11.5.1 Cumberland Pharmaceuticals Company Detail
        11.5.2 Cumberland Pharmaceuticals Business Overview
        11.5.3 Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Introduction
        11.5.4 Cumberland Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
        11.5.5 Cumberland Pharmaceuticals Recent Development
    11.6 Santhera Pharmaceuticals
        11.6.1 Santhera Pharmaceuticals Company Detail
        11.6.2 Santhera Pharmaceuticals Business Overview
        11.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Introduction
        11.6.4 Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
        11.6.5 Santhera Pharmaceuticals Recent Development
    11.7 Taiho Pharmaceutical
        11.7.1 Taiho Pharmaceutical Company Detail
        11.7.2 Taiho Pharmaceutical Business Overview
        11.7.3 Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Introduction
        11.7.4 Taiho Pharmaceutical Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
        11.7.5 Taiho Pharmaceutical Recent Development
    11.8 Teijin Pharma
        11.8.1 Teijin Pharma Company Detail
        11.8.2 Teijin Pharma Business Overview
        11.8.3 Teijin Pharma Duchenne Muscular Dystrophy Drugs Introduction
        11.8.4 Teijin Pharma Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
        11.8.5 Teijin Pharma Recent Development
    11.9 Akashi Therapeutics
        11.9.1 Akashi Therapeutics Company Detail
        11.9.2 Akashi Therapeutics Business Overview
        11.9.3 Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Introduction
        11.9.4 Akashi Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
        11.9.5 Akashi Therapeutics Recent Development
    11.10 Sarepta Therapeutics
        11.10.1 Sarepta Therapeutics Company Detail
        11.10.2 Sarepta Therapeutics Business Overview
        11.10.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Introduction
        11.10.4 Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
        11.10.5 Sarepta Therapeutics Recent Development
    11.11 BioMarin
        11.11.1 BioMarin Company Detail
        11.11.2 BioMarin Business Overview
        11.11.3 BioMarin Duchenne Muscular Dystrophy Drugs Introduction
        11.11.4 BioMarin Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
        11.11.5 BioMarin Recent Development
    11.12 Fibrogen Inc
        11.12.1 Fibrogen Inc Company Detail
        11.12.2 Fibrogen Inc Business Overview
        11.12.3 Fibrogen Inc Duchenne Muscular Dystrophy Drugs Introduction
        11.12.4 Fibrogen Inc Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
        11.12.5 Fibrogen Inc Recent Development
    11.13 Nobelpharma Co. Ltd
        11.13.1 Nobelpharma Co. Ltd Company Detail
        11.13.2 Nobelpharma Co. Ltd Business Overview
        11.13.3 Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Introduction
        11.13.4 Nobelpharma Co. Ltd Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
        11.13.5 Nobelpharma Co. Ltd Recent Development
    11.14 Eloxx Pharmaceuticals
        11.14.1 Eloxx Pharmaceuticals Company Detail
        11.14.2 Eloxx Pharmaceuticals Business Overview
        11.14.3 Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Introduction
        11.14.4 Eloxx Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
        11.14.5 Eloxx Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details

List of Tables
    Table 1. Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
    Table 2. Key Players of Molecular-based Therapies
    Table 3. Key Players of Steroid Therapy
    Table 4. Key Players of Other
    Table 5. Global Duchenne Muscular Dystrophy Drugs Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
    Table 6. Global Duchenne Muscular Dystrophy Drugs Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 7. Global Duchenne Muscular Dystrophy Drugs Market Size by Region (2017-2022) & (US$ Million)
    Table 8. Global Duchenne Muscular Dystrophy Drugs Market Share by Region (2017-2022)
    Table 9. Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 10. Global Duchenne Muscular Dystrophy Drugs Market Share by Region (2023-2028)
    Table 11. Duchenne Muscular Dystrophy Drugs Market Trends
    Table 12. Duchenne Muscular Dystrophy Drugs Market Drivers
    Table 13. Duchenne Muscular Dystrophy Drugs Market Challenges
    Table 14. Duchenne Muscular Dystrophy Drugs Market Restraints
    Table 15. Global Duchenne Muscular Dystrophy Drugs Revenue by Players (2017-2022) & (US$ Million)
    Table 16. Global Duchenne Muscular Dystrophy Drugs Market Share by Players (2017-2022)
    Table 17. Global Top Duchenne Muscular Dystrophy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy Drugs as of 2021)
    Table 18. Ranking of Global Top Duchenne Muscular Dystrophy Drugs Companies by Revenue (US$ Million) in 2021
    Table 19. Global 5 Largest Players Market Share by Duchenne Muscular Dystrophy Drugs Revenue (CR5 and HHI) & (2017-2022)
    Table 20. Key Players Headquarters and Area Served
    Table 21. Key Players Duchenne Muscular Dystrophy Drugs Product Solution and Service
    Table 22. Date of Enter into Duchenne Muscular Dystrophy Drugs Market
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Duchenne Muscular Dystrophy Drugs Market Size by Type (2017-2022) & (US$ Million)
    Table 25. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Type (2017-2022)
    Table 26. Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 27. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Type (2023-2028)
    Table 28. Global Duchenne Muscular Dystrophy Drugs Market Size by Application (2017-2022) & (US$ Million)
    Table 29. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Application (2017-2022)
    Table 30. Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 31. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Application (2023-2028)
    Table 32. North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2017-2022) & (US$ Million)
    Table 33. North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2028) & (US$ Million)
    Table 34. Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2017-2022) & (US$ Million)
    Table 35. Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2028) & (US$ Million)
    Table 36. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region (2017-2022) & (US$ Million)
    Table 37. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region (2023-2028) & (US$ Million)
    Table 38. Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2017-2022) & (US$ Million)
    Table 39. Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2028) & (US$ Million)
    Table 40. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country (2017-2022) & (US$ Million)
    Table 41. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2028) & (US$ Million)
    Table 42. Biogen Company Detail
    Table 43. Biogen Business Overview
    Table 44. Biogen Duchenne Muscular Dystrophy Drugs Product
    Table 45. Biogen Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
    Table 46. Biogen Recent Development
    Table 47. Roche Company Detail
    Table 48. Roche Business Overview
    Table 49. Roche Duchenne Muscular Dystrophy Drugs Product
    Table 50. Roche Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
    Table 51. Roche Recent Development
    Table 52. Daiichi Sankyo Company Detail
    Table 53. Daiichi Sankyo Business Overview
    Table 54. Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Product
    Table 55. Daiichi Sankyo Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
    Table 56. Daiichi Sankyo Recent Development
    Table 57. Pfizer Company Detail
    Table 58. Pfizer Business Overview
    Table 59. Pfizer Duchenne Muscular Dystrophy Drugs Product
    Table 60. Pfizer Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
    Table 61. Pfizer Recent Development
    Table 62. Cumberland Pharmaceuticals Company Detail
    Table 63. Cumberland Pharmaceuticals Business Overview
    Table 64. Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product
    Table 65. Cumberland Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
    Table 66. Cumberland Pharmaceuticals Recent Development
    Table 67. Santhera Pharmaceuticals Company Detail
    Table 68. Santhera Pharmaceuticals Business Overview
    Table 69. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product
    Table 70. Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
    Table 71. Santhera Pharmaceuticals Recent Development
    Table 72. Taiho Pharmaceutical Company Detail
    Table 73. Taiho Pharmaceutical Business Overview
    Table 74. Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Product
    Table 75. Taiho Pharmaceutical Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
    Table 76. Taiho Pharmaceutical Recent Development
    Table 77. Teijin Pharma Company Detail
    Table 78. Teijin Pharma Business Overview
    Table 79. Teijin Pharma Duchenne Muscular Dystrophy Drugs Product
    Table 80. Teijin Pharma Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
    Table 81. Teijin Pharma Recent Development
    Table 82. Akashi Therapeutics Company Detail
    Table 83. Akashi Therapeutics Business Overview
    Table 84. Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Product
    Table 85. Akashi Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
    Table 86. Akashi Therapeutics Recent Development
    Table 87. Sarepta Therapeutics Company Detail
    Table 88. Sarepta Therapeutics Business Overview
    Table 89. Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Product
    Table 90. Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
    Table 91. Sarepta Therapeutics Recent Development
    Table 92. BioMarin Company Detail
    Table 93. BioMarin Business Overview
    Table 94. BioMarin Duchenne Muscular Dystrophy DrugsProduct
    Table 95. BioMarin Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
    Table 96. BioMarin Recent Development
    Table 97. Fibrogen Inc Company Detail
    Table 98. Fibrogen Inc Business Overview
    Table 99. Fibrogen Inc Duchenne Muscular Dystrophy DrugsProduct
    Table 100. Fibrogen Inc Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
    Table 101. Fibrogen Inc Recent Development
    Table 102. Nobelpharma Co. Ltd Company Detail
    Table 103. Nobelpharma Co. Ltd Business Overview
    Table 104. Nobelpharma Co. Ltd Duchenne Muscular Dystrophy DrugsProduct
    Table 105. Nobelpharma Co. Ltd Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
    Table 106. Nobelpharma Co. Ltd Recent Development
    Table 107. Eloxx Pharmaceuticals Company Detail
    Table 108. Eloxx Pharmaceuticals Business Overview
    Table 109. Eloxx Pharmaceuticals Duchenne Muscular Dystrophy DrugsProduct
    Table 110. Eloxx Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
    Table 111. Eloxx Pharmaceuticals Recent Development
    Table 112. Research Programs/Design for This Report
    Table 113. Key Data Information from Secondary Sources
    Table 114. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Duchenne Muscular Dystrophy Drugs Market Share by Type: 2021 VS 2028
    Figure 2. Molecular-based Therapies Features
    Figure 3. Steroid Therapy Features
    Figure 4. Other Features
    Figure 5. Global Duchenne Muscular Dystrophy Drugs Market Share by Application in 2021 & 2028
    Figure 6. Hospitals Case Studies
    Figure 7. Clinics Case Studies
    Figure 8. Others Case Studies
    Figure 9. Duchenne Muscular Dystrophy Drugs Report Years Considered
    Figure 10. Global Duchenne Muscular Dystrophy Drugs Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 11. Global Duchenne Muscular Dystrophy Drugs Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 12. Global Duchenne Muscular Dystrophy Drugs Market Share by Region: 2021 VS 2028
    Figure 13. Global Duchenne Muscular Dystrophy Drugs Market Share by Players in 2021
    Figure 14. Global Top Duchenne Muscular Dystrophy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy Drugs as of 2021)
    Figure 15. The Top 10 and 5 Players Market Share by Duchenne Muscular Dystrophy Drugs Revenue in 2021
    Figure 16. North America Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 17. North America Duchenne Muscular Dystrophy Drugs Market Share by Country (2017-2028)
    Figure 18. United States Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 19. Canada Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 20. Europe Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 21. Europe Duchenne Muscular Dystrophy Drugs Market Share by Country (2017-2028)
    Figure 22. Germany Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 23. France Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 24. U.K. Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 25. Italy Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 26. Russia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 27. Nordic Countries Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Share by Region (2017-2028)
    Figure 30. China Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. Japan Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. South Korea Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. Southeast Asia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. India Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 35. Australia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 36. Latin America Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 37. Latin America Duchenne Muscular Dystrophy Drugs Market Share by Country (2017-2028)
    Figure 38. Mexico Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. Brazil Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Share by Country (2017-2028)
    Figure 42. Turkey Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 43. Saudi Arabia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 44. Biogen Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
    Figure 45. Roche Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
    Figure 46. Daiichi Sankyo Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
    Figure 47. Pfizer Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
    Figure 48. Cumberland Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
    Figure 49. Santhera Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
    Figure 50. Taiho Pharmaceutical Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
    Figure 51. Teijin Pharma Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
    Figure 52. Akashi Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
    Figure 53. Sarepta Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
    Figure 54. BioMarin Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
    Figure 55. Fibrogen Inc Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
    Figure 56. Nobelpharma Co. Ltd Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
    Figure 57. Eloxx Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
    Figure 58. Bottom-up and Top-down Approaches for This Report
    Figure 59. Data Triangulation
    Figure 60. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Biogen
Roche
Daiichi Sankyo
Pfizer
Cumberland Pharmaceuticals
Santhera Pharmaceuticals
Taiho Pharmaceutical
Teijin Pharma
Akashi Therapeutics
Sarepta Therapeutics
BioMarin
Fibrogen Inc
Nobelpharma Co. Ltd
Eloxx Pharmaceuticals
Frequently Asked Questions
Duchenne Muscular Dystrophy Drugs report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Duchenne Muscular Dystrophy Drugs report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Duchenne Muscular Dystrophy Drugs report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Dumplings

The research report includes specific segments by region (country), by company, by Type and by Ap ... Read More

Dyslipidemia Drugs

Dyslipidemia Drugs market is segmented by players, region (country), by Type and by Application.  ... Read More